ClinicalTrials.gg
RecruitingNCT07400952Updated Feb 10, 2026

Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus

A Phase 2 interventional study of GLK-221 Ophthalmic Solution and Placebo Ophthalmic Solution in Keratoconus, sponsored by Glaukos Corporation. Recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by Glaukos Corporation · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 94 studies in Keratoconus with a site in United States — 27 open to participants now, 33 under way, 9 of them phase 3. Keratoconus · United States.

Planned enrollment
38th of 71
100 · median 147
Started
2025
with 5 others
Phase 2
12 of 94
3 open now
Primary completion
2027-04
later than 14 of 32 live
Registered
88th of 94
by date
Lead sponsor
8 of 94
Glaukos Corporation

Among the 94 studies in Keratoconus with a site in United States, this one is the 38th largest by planned enrollment of the 71 interventional ones that give a count, is one of 6 that started in 2025, is one of 12 in phase 2, reaches primary completion later than 14 of the 32 other live ones, and was the 88th registered.

Keratoconus

313 studies on the registry are indexed under Keratoconus; 56 are open to participants now.

Browse Keratoconus studies →

Open to participants now

27 of the 94 studies in Keratoconus with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 37 Keratoconus studies recruiting now, 21 (57%) set no upper age limit and 11 (30%) stop at 75 or younger; 17 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies in Keratoconus with a site in United States, or all of them as a file.
02

Study summary

Multi-center, parallel-group, placebo-controlled trial designed to assess the safety and efficacy of twice-daily topically administered GLK-221 Ophthalmic Solution in subjects with keratoconus.

03

Conditions studied

  • Keratoconus

Browse trials for

Keywords

  • Keratoconus
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be ≥ 18 and ≤ 55 years of age
  • Diagnosis of keratoconus in the study eye

Exclusion criteria

Exclusion Criteria:

  • Pregnant, lactating or planning a pregnancy
  • Currently enrolled, or within 30 days prior to Screening were enrolled, in another drug or device trial
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    GLK-221 Ophthalmic Solution

    GLK-221 Ophthalmic Solution administered topically twice daily to both eyes

    Drug: GLK-221 Ophthalmic Solution

  • Placebo comparator
    Placebo

    Placebo Ophthalmic Solution administered topically twice daily to both eyes

    Drug: Placebo Ophthalmic Solution

Interventions

  • DrugGLK-221 Ophthalmic Solution

    GLK-221 Ophthalmic Solution administered twice daily to both eyes

  • DrugPlacebo Ophthalmic Solution

    Placebo Ophthalmic Solution administered twice daily to both eyes

06

What researchers measure

Primary outcomes

  1. Mean change from baseline in maximum corneal curvature

    Mean change from baseline in maximum corneal curvature

    Time frame: 16 weeks

07

Study locations

1 of 1 sites recruiting
  • Glaukos Clinical Study Site
    Westerville, Ohio 43082, United States
    Recruiting
    • Study Manager · Contact949-739-8749
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Apr 2027, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2026
First posted
Feb 10, 2026
StartActual
Dec 23, 2025
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07400952
Responsible party
Sponsor
First posted
Feb 10, 2026
Start date
Dec 23, 2025
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Feb 10, 2026

Study contacts

Study Manager
Contact
ClinicalResearch@Glaukos.com
949-739-8749
Study Director, MD
study director · Glaukos Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion